Insider trades
Orbimed Capital, Director of Prelude Therapeutics PRLD, has filed 18 purchases and 5 sales on the open market. Over the past 12 months that comes to a net purchase of $12.5M. The latest trade was on 04/21.
Orbimed Capital
Director
- Company
- Prelude Therapeutics PRLD
- First filing
- 23/02/23
- Trades
- 30 trades
- Buys / sales
- 18 / 5
- 12-month net buying
- $12.5M
- Last trade
- 04/21
Trading activity
Transactions
| Trade type | |||||||
|---|---|---|---|---|---|---|---|
PRLD | Open-market buy | 04/21 | 04/23 | 2,815,315 sh2 trades | $4.44avg. | $12,499,998.6 | No record |
| Open-market sale | 24/08/26 | 24/08/28 | 83,695 sh | $13.00 | $1,088,035 | −100.0% | |
SPRY | Open-market sale | 24/08/21–24/08/23 | 24/08/23 | 868,682 sh4 trades | $13.24avg. | $11,497,963.08 | −91.2% |
| Open-market buy | 23/08/29 | 23/08/31 | 500,000 sh | $6.20 | $3,100,000 | +6.6% | |
| Open-market buy | 23/05/22 | 23/05/24 | 869,565 sh | $5.75 | $4,999,998.75 | +9.4% | |
| Open-market buy | 23/05/04–23/05/05 | 23/05/08 | 1,460,932 sh5 trades | $2.80avg. | $4,086,234.61 | No record | |
| Open-market buy | 23/04/28–23/05/02 | 23/05/02 | 1,405,168 sh9 trades | $2.61avg. | $3,673,900.83 | No record |
